49 related articles for article (PubMed ID: 23995446)
1. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
Redmer T; Raigel M; Sternberg C; Ziegler R; Probst C; Lindner D; Aufinger A; Limberger T; Trachtova K; Kodajova P; Högler S; Schlederer M; Stoiber S; Oberhuber M; Bolis M; Neubauer HA; Miranda S; Tomberger M; Harbusch NS; Garces de Los Fayos Alonso I; Sternberg F; Moriggl R; Theurillat JP; Tichy B; Bystry V; Persson JL; Mathas S; Aberger F; Strobl B; Pospisilova S; Merkel O; Egger G; Lagger S; Kenner L
Mol Cancer; 2024 May; 23(1):114. PubMed ID: 38811984
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic ETS Factors in Prostate Cancer.
Nicholas TR; Strittmatter BG; Hollenhorst PC
Adv Exp Med Biol; 2019; 1210():409-436. PubMed ID: 31900919
[TBL] [Abstract][Full Text] [Related]
3. Understanding the temporal sequence of genetic events that lead to prostate cancer progression and metastasis.
Baker SJ; Reddy EP
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):14819-20. PubMed ID: 23995446
[No Abstract] [Full Text] [Related]
4. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
Zong Y; Xin L; Goldstein AS; Lawson DA; Teitell MA; Witte ON
Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12465-70. PubMed ID: 19592505
[TBL] [Abstract][Full Text] [Related]
5. SPDEF: a molecular switch for E-cadherin expression that promotes prostate cancer metastasis.
Osisami M; Keller ET
Asian J Androl; 2013 Sep; 15(5):584-5. PubMed ID: 23708459
[No Abstract] [Full Text] [Related]
6. PDEF in prostate cancer.
Sood AK; Kim H; Geradts J
Prostate; 2012 May; 72(6):592-6. PubMed ID: 21796651
[TBL] [Abstract][Full Text] [Related]
7. A tight junction between E-Cadherin and the prostate tumor suppressor SPDEF.
Coppola V; Bonci D
Asian J Androl; 2013 Jul; 15(4):449-50. PubMed ID: 23708463
[No Abstract] [Full Text] [Related]
8. Targeted therapy in the treatment of castration-resistant prostate cancer.
Derleth CL; Yu EY
Oncology (Williston Park); 2013 Jul; 27(7):620-8. PubMed ID: 23977754
[TBL] [Abstract][Full Text] [Related]
9. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.
Aytes A; Mitrofanova A; Kinkade CW; Lefebvre C; Lei M; Phelan V; LeKaye HC; Koutcher JA; Cardiff RD; Califano A; Shen MM; Abate-Shen C
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):E3506-15. PubMed ID: 23918374
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition.
Pellecchia A; Pescucci C; De Lorenzo E; Luceri C; Passaro N; Sica M; Notaro R; De Angioletti M
Oncogenesis; 2012 Jul; 1(7):e20. PubMed ID: 23552736
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
12. Cancer statistics, 2013.
Siegel R; Naishadham D; Jemal A
CA Cancer J Clin; 2013 Jan; 63(1):11-30. PubMed ID: 23335087
[TBL] [Abstract][Full Text] [Related]
13. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells.
Mulholland DJ; Kobayashi N; Ruscetti M; Zhi A; Tran LM; Huang J; Gleave M; Wu H
Cancer Res; 2012 Apr; 72(7):1878-89. PubMed ID: 22350410
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
